Daniel Long Sells 3,334 Shares of Septerna (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,334 shares of Septerna stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $34.47, for a total value of $114,922.98. Following the sale, the senior vice president owned 96,412 shares of the company’s stock, valued at approximately $3,323,321.64. This represents a 3.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Septerna Stock Performance

SEPN stock traded down $0.22 during trading on Wednesday, hitting $38.76. The stock had a trading volume of 442,941 shares, compared to its average volume of 348,687. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -47.85 and a beta of 2.29. The company’s 50 day moving average price is $33.88 and its two-hundred day moving average price is $28.75. Septerna, Inc. has a 1-year low of $10.62 and a 1-year high of $40.63.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.23. The company had revenue of $26.52 million for the quarter, compared to analysts’ expectations of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, sell-side analysts forecast that Septerna, Inc. will post -1.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on SEPN. Guggenheim decreased their target price on shares of Septerna from $52.00 to $45.00 and set a “buy” rating on the stock in a research report on Wednesday, July 1st. Stifel Nicolaus assumed coverage on Septerna in a report on Friday, May 1st. They issued a “buy” rating and a $43.00 price target for the company. Truist Financial increased their price target on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Raymond James Financial raised their price objective on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a report on Monday, June 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Septerna in a research report on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Septerna has a consensus rating of “Moderate Buy” and a consensus price target of $45.89.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Woodline Partners LP lifted its position in Septerna by 94.2% during the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after buying an additional 282,585 shares in the last quarter. Rhumbline Advisers increased its position in shares of Septerna by 16.6% in the first quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after acquiring an additional 3,323 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Septerna by 19.1% in the second quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock worth $5,158,000 after acquiring an additional 78,316 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after acquiring an additional 1,315 shares during the period. Finally, CW Advisors LLC purchased a new position in shares of Septerna in the 2nd quarter valued at $133,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.